Abstract 774P
Background
Around 50% of HGOC is characterized as negative for homologous recombination deficiency (HRDneg) based on lack of BRCA mutation and low genomic instability score (GIS). ∼15% of HGOC patients harbor CCNE1 amplification (CCNE1amp) which has been presumed to be associated with chemoresistance, HRDneg and poor prognosis. We aimed to determine the genomic profiles and outcome of CCNE1amp HGOC in comparison to non-CCNE1amp HRDneg HGOC.
Methods
We conducted a retrospective analysis of patients (pts) with advanced HGOC (excluding clear-cell and mucinous histology) with available genomic data from Institut Gustave Roussy, France and National University Cancer Institute, Singapore. CCNE1amp BRCA1/2 and RAD51C/D mutations were detected by next-generation sequencing on tumor samples. GIS was evaluated by Myriad MyChoice or Foundation Medicine LOH. Progression free survival (PFS) (date of diagnosis to first progression) and pathological response to neoadjuvant chemotherapy by chemotherapy response score (CRS) were collected.
Results
We identified 55 CCNE1amp and 104 HRDneg non-CCNE1amp tumors. Pts with CCNE1amp tumor were significantly older (64 versus 61.5 years, p<0.01). Overall, 81% were high-grade serous, 8% carcinosarcomas, and 62% benefited from complete cytoreductive surgery. As expected, no BRCA1/2 or RAD51C/D mutations were detected in the CCNE1amp cohort. 19% of CCNE1amp tumors were classified HRD positive and 81% HRDneg. Among CCNE1amp, 31% of patients experienced a good pathological response (CRS3) versus 18% in the HRDneg cohort (p=0.26). Median PFS was 21.1 months in the CCNE1amp cohort versus 14.2 months in the HRDneg cohort (p=0.008) and median overall survival was 55.3 months versus 42.9 months (p=0.044). In multivariate analysis including completeness of surgery, CCNE1amp was statistically associated with better PFS, HR=1.6 (95%CI 1.06-2.5).
Conclusions
We report clinical and molecular features associated with CCNE1 amplification in advanced HGOC. As expected CCNE1 amplifications are mutually exclusive from BRCA mutations, however 20% were HRD according to GIS. We observed unexpected high rates of CRS3, and significantly improved outcomes compared to non-CCNE1amp HRDneg tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blanc-Durand: Financial Interests, Personal, Speaker, Consultant, Advisor: Eisai; Financial Interests, Personal, Other: GSK; Financial Interests, Institutional, Research Grant: AZ; Financial Interests, Personal, Steering Committee Member: Cureety. N.Y.L. Ngoi: Financial Interests, Institutional, Invited Speaker: MSD, AstraZeneca, ASGO, JSGO; Financial Interests, Institutional, Advisory Board: Merck/Pfizer, AstraZeneca. P. Pautier: Financial Interests, Personal, Advisory Board, 2015, 2022: PharmaMar; Financial Interests, Institutional, Advisory Board, 2020: Roche, Clovis; Financial Interests, Institutional, Advisory Board, 2021: AstraZeneca; Financial Interests, Personal, Advisory Board, 2019-2020: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, 2018-2019: Roche; Financial Interests, Institutional, Advisory Board, 2022: MSD; Financial Interests, Personal and Institutional, Research Grant: PharmaMar; Financial Interests, Research Grant: ONXEO. K. Ouali: Financial Interests, Institutional, Other, As part of the Drug Development Department (DITEP), KO is principal/sub-Investigator of Clinical Trials for AbbVie, Adaptimmune, Adlai Nortye USA Inc., Aduro Biotech, Agios Pharmaceuticals, Amgen, AstraZeneca Ab, AstraZeneca, Aveo, Basilea Pharmaceutica International Ltd., Bayer Healthcare Ag, BeiGene, BicycleTx Ltd., Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Casi Pharmaceuticals, Inc., Cato Research, Celgene Corporation, Cellcentric, Chugai Pharmaceutical Co, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, EverImmune, Exelixis, Faron Pharmaceuticals Ltd., Foghorn Therapeutics Inc., Forma Tharapeutics, Gamamabs, Genentech, Genmab, GSK, H3 Biomedicine, F. Hoffmann-La Roche AG, IGM Biosciences, Imcheck Therapeutics, Incyte Corporation, Innate Pharma, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Janssen R&D LLC, K-Group Beta, Kinnate Biopharma, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France,: Various drug companies. A. Leary: Financial Interests, Personal, Advisory Board: Zentalis; Financial Interests, Personal, Invited Speaker, Educational: GSK, Medscape; Financial Interests, Personal, Writing Engagement, Educational: Onko+; Financial Interests, Institutional, Other, Steering committee: MSD; Financial Interests, Institutional, Advisory Board: GSK, AZ, Clovis, Ability Pharma, MSD, Merck Serono, Apmonia, Blueprint; Financial Interests, Institutional, Invited Speaker, Educational: Kephren publishing; Financial Interests, Institutional, Other, Consultancy: Orion; Financial Interests, Institutional, Invited Speaker: AZ, Clovis; Financial Interests, Personal, Other, Consultancy: GLG; Financial Interests, Institutional, Research Grant, PI translational research: ARCAGY-GINECO, Sanofi, AZ; Financial Interests, Institutional, Funding, CI clinical trial: AZ; Financial Interests, Institutional, Research Grant, Int CI clinical trial: OSE Immuno; Financial Interests, Institutional, Funding, PI clinical trial: Agenus, BMS, Iovance, GSK; Financial Interests, Institutional, Funding, PI 5 clinical trials: Roche; Financial Interests, Institutional, Funding, PI 2 clinical trials: AZ; Financial Interests, Institutional, Funding, PI 3 clinical trials and steering committee: MSD; Non-Financial Interests, Institutional, Other, Academic research project: Owkin, LXRepair; Non-Financial Interests, Personal, Proprietary Information, IDMC member: Clovis; Non-Financial Interests, Personal, Proprietary Information, IDMC chair: Pfizer; Non-Financial Interests, Member: GCIG. D.S. Tan: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Merck Serono, Roche, Eisai, GSK, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, MSD, Eisai, Roche, Genmab, GSK, Boehringer Ingelheim; Financial Interests, Personal, Stocks/Shares: Asian Microbiome Library (AMiLi); Financial Interests, Institutional, Research Grant: Roche, Bayer, Karyopharm Therapeutics, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bergen Bio; Financial Interests, Institutional, Local PI: Zeria Pharmaceutical Co Ltd., Bayer, Byondis B.V.; Non-Financial Interests, Leadership Role, Ex society president: Gynecologic Cancer Group Singapore; Non-Financial Interests, Member of Board of Directors: Gynaecologic Cancer Intergroup (GCIG); Non-Financial Interests, Leadership Role, Ex- Chair: Asia-Pacific Gynecologic Oncology Trials Group (APGOT); Non-Financial Interests, Institutional, Product Samples, Research Study: MSD, Eisai, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11